Printer Friendly

UNIVERSITY OF LONDON INDEPENDENT LAB STUDIES VERIFY POWERFUL ANTI- OXIDANT PROPERTIES OF ADVANCED BIOLOGICAL SYSTEMS' AIDS COMPOUNDS

 UNIVERSITY OF LONDON INDEPENDENT LAB STUDIES VERIFY POWERFUL ANTI-
 OXIDANT PROPERTIES OF ADVANCED BIOLOGICAL SYSTEMS' AIDS COMPOUNDS
 SALT LAKE CITY, May 18 /PRNewswire/ -- Results of just-completed independent studies at a leading British university have confirmed the presence of powerful anti-oxidant properties in a family of plant-based, non-toxic substances used to treat AIDS, according to Emanuel A. Floor, CEO of Advanced Biological Systems, Inc. (OTC: Bulletin Board), the American company that holds distribution rights to the compounds.
 The studies provide the first laboratory evidence of a mechanism through which the plant extracts may act to limit the effects of the human immunodeficiency virus (HIV) in the body. It is believed the treatment program also has a positive moderating effect on a patient's immune system.
 The London research, says Howard C. Greenspan, director of research and development for Advanced Biological Systems, provides a possible scientific basis for the positive results seen in patients, to date.
 Developed by Swiss physician, Jozsef Roka, the three compounds tested in the independent studies, commonly known as Carciviren IV, Rovital, and Carciviren IM, have proved beneficial in the treatment of a substantial number of the over 300 advanced HIV-infected patients seen at Roka's Zurich clinic and in Tanzania where they were treated in cooperation with that nation's Ministry of Health. Those patients experienced notable overall energy and health improvement as well as important weight gain. None have reported any significant side effects.
 The studies, conducted by researchers at the University of London's Kings College Department of Biochemistry, consisted of a series of laboratory tests on substances that measure the activity of reactive oxygen compounds and free radicals, both of which have been associated with immune system diseases. In each test, the "scavenger" activity of the three plant-based substances developed by Roka was analyzed.
 The researchers concluded that Rovital, Carciviren IV, and Carciviren IM are "powerful scavengers of hydroxyl radicals." "Scavengers" search for, and destroy, forms of reactive oxygen and free radicals that can be harmful when present in the body in excess.
 According to Greenspan, current research indicates that excessive "oxidative stress" in HIV-infected individuals, particularly hydroxyl radicals, may be responsible for triggering the replication of HIV which otherwise remains dormant. An excess of free radicals, he noted, has been implicated in a broad range of degenerative and inflammatory illnesses including heart disease, cancer, arthritis, and cataracts.
 In recent years, increasing attention has been given to the anti- oxidant role of plant extracts. Theories for the efficacy of the Roka treatment have suggested possible anti-oxidant properties as well as direct immune system stimulation.
 The Roka treatment program is currently available through a licensing agreement between Advanced Biological Systems and a medical clinic in the Caribbean area. The company is also sponsoring additional clinical studies and tests which it hopes will lead to the registration of the products for use in other jurisdictions.
 Advanced Biological Systems, Inc., a publicly-owned Delaware corporation is engaged in the acquisition, development, and marketing of plant-source products and in the delivery of care for immune deficiency conditions through treatments which include those products.
 -0- 5/18/92
 /CONTACT: Paul Mortensen or Howard Greenspan of Advanced Biological Systems, 801-521-8000/ CO: Advanced Biological Systems Inc. ST: California IN: MTC SU:


SH -- NY023 -- 1221 05/18/92 10:25 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 18, 1992
Words:544
Previous Article:GTE TO SUPPLY CABIN EQUIPMENT FOR LUFTHANSA'S TRIAL OF SATELLITE- COMMUNICATIONS SERVICE; GTE'S FIRST TRIAL WITH A EUROPEAN AIRLINE
Next Article:CARL MARKS & CO., INC. ANNOUNCES FORMATION OF NEW FINANCIAL AND MANAGEMENT CONSULTING GROUP
Topics:


Related Articles
ADVANCED BIOLOGICAL SYSTEMS REPORTS ADDITIONAL, FAVORABLE TOXICITY TESTS FOR PLANT-BASED AIDS DRUGS, C-1983 AND R-1103
PROTEIN DESIGN LABS ANNOUNCES RESULTS OF CMV RETINITIS TRIAL IN AIDS PATIENTS
AGOURON PHARMACEUTICALS EXPANDS CLINICAL TESTING OF SECOND CANCER DRUG INTO UNITED STATES
PHARMA MAR, S.A. ANNOUNCES MAJOR COLLABORATION WITH MAJOR EUROPEAN INSTITUTION
PHASE II TRIAL BEGINS WITH PDL'S HUMAN ANTI-CMV ANTIBODY IN AIDS PATIENTS WITH CMV RETINITIS
PRELIMINARY PHASE I DATA REPORTED ON VERTEX GLAXO WELLCOME HIV PROTEASE INHIBITOR
NATURAL CEUTICALS INC. SAYS RARE GRAPE SPECIES YIELDS HIGHEST CONCENTRATION OF CANCER/HEART DISEASE-FIGHTING PHYTO-CHEMICALS
SunPharm to Provide Additional Data 0n Anti-Diarrhea Compound.
Immtech establishes anti-fungal consortium and receives new patents to focus exclusively on developing anti-fungal drugs.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters